·The Hindu·15 marks·250–350 words

Rapid advances in gene editing have outpaced regulatory frameworks. Discuss in the light of recent controversies, and suggest a governance architecture for India.

New · District CollectorCan you hold the district for 72 hours?Floods, a heatwave, an outbreak, a grievance queue. Take the decisions, see the consequences.Play →
In this answer
  1. How technology outpaced regulation: recent controversies
  2. Gaps in India
  3. Suggested governance architecture

Gene editing tools like CRISPR now move from the lab to child patients within a few years, but oversight still mostly acts after harm is done. In November 2026, Shanghai authorities dismissed neuroscientist Zilong Qiu. A six-year-old had died in his trial, and the death was left out of his Nature paper [1]. The case shows regulation falling behind innovation.

How technology outpaced regulation: recent controversies

  • Hidden harm: A girl with non-life-threatening Snijders Blok-Campeau syndrome died in 2025 after experimental gene therapy. The February 2026 paper did not mention her. Only an investigation by Science and Retraction Watch exposed the omission [1].
  • Institutional failure: Hospital-linked staff were also punished, so ethics review failed, not just one scientist [1].
  • Reactive enforcement: Dismissal, a five-year ban and an entry in a research-integrity database came only after the media exposed the case [1].
  • Germline precedent: The 2018 case of gene-edited babies led WHO to set up an Expert Advisory Committee. WHO considers heritable editing of greater ethical concern [2][3].
  • Cross-border risk: WHO's 2021 framework warns against somatic trials where oversight is weak. It also flags medical travel [2].

Gaps in India

  • Fragmented oversight: Lab biosafety falls under RCGM (1989 Rules) [5]. Trials fall under CDSCO's 2019 Gene Therapy Guidelines [4]. No single body makes sure animal-study data reaches ethics committees.
  • Lagging rules: DBT's 2020 genome-editing framework is still a draft [6].
  • Thin capacity: CDSCO's generalist structure lacks expertise in complex biologics [7]. Meanwhile BIRSA-101, India's home-grown CRISPR therapy for sickle cell disease, is nearing patients [4].

Suggested governance architecture

  • Dedicated law that sets out the somatic–germline distinction.
  • Specialist gene-therapy cell within CDSCO [7].
  • Mandatory prior registration of every trial, following WHO's registry recommendation [2].
  • Compulsory hand-off of animal-study data to hospital ethics committees before the first patient is treated.
  • Whistle-blower channel for reporting unsafe research [2].
  • Funding conditions: DBT and ICMR recover grants when serious adverse events go unreported.

The Shanghai case and India's split oversight both show that punishing misconduct afterwards cannot replace checks before treatment. India should put in place a registry, specialist review and mandatory reporting before BIRSA-101 scales up. That would protect the right to health under Article 21 and advance SDG 3, while supporting innovation that patients can trust.

Sources

  1. 1Chinese scientist fired after child death in gene-editing trial: state media — The Hindu (AFP), Nov 2026Qiu's dismissal, the 2025 death left out of the Feb 2026 *Nature* paper, the *Science*/*Retraction Watch* exposé, the five-year ban, punishment of hospital staff (homepage only: the article page could not be checked because the site blocks automated access)
  2. 2WHO issues new recommendations on human genome editing for the advancement of public health (12 July 2021)Expert Advisory Committee, governance framework, registry, unsafe-research reporting, medical travel, weak-oversight caution
  3. 3WHO — Human genome editing (health topic)heritable editing of greater ethical concern
  4. 4PIB — Parliament Question: Self reliance in CRISPR and gene editing2019 National Gene Therapy Guidelines (CDSCO–ICMR–DBT), BIRSA-101
  5. 5PIB — Parliament Question: Research and regulation in synthetic biologyRCGM biosafety oversight under the 1989 Rules, Environment (Protection) Act
  6. 6DBT — Invitation for comments on Draft Document on Genome Edited Organisms: Regulatory Framework and Guidelines (Jan 2020)2020 genome-editing framework still at draft stage
  7. 7PIB — Press Release on the 175th, 176th and 177th Reports of the Parliamentary Standing Committee on Health & Family WelfareCDSCO's generalist structure lacks expertise for complex biologics

More from this note